zurück Home

Stereotactic body-radiation therapy, SBRT

Allgemeines

Dosis

 60-66 Gy in 3 Fraktionen.

lokale Kontrolle

Bei NSCLC Stadium I werden Kontrollraten über 90% erreicht (1,2).

Rezidive (3)

Patienten 676 von 2003-11 mit NSCLC Stadium 1 - 2, PET-Staging
Rezidiv-Rate medianer Follow up: 32,9Monate: 124 Rezidive insgesamt. 42 pulmonale 2.-Tumoren
Lokalrezidive regionale Rezidive Fernmetastasen
2 Jahre 4,9% 7,8% 14,7%
5 Jahre 10,5% 12,7% 19,9%

Quellen

 1.) Lo SS, et al.:
Stereotactic body radiation therapy: a novel treatment modality.
Nat Rev Clin Oncol 7(2010):44-54

2.) Timmerman R, et al.:
Stereotactic body radiation therapy for inoperable early stage lung cancer.
JAMA 303(2010):1070-6

3.) Senthi S, et al.:
Patters of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer:a retrospective analysis.
Lancet Oncol 13(2012):802-809

4.) Guckenberger M, Allgauer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, et al.:
Safety and efficacy of stereotactic body radiotherapy for stage i non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis.
J Thorac Oncol. 2013;8:1050-8

5.) Verstegen NE, Oosterhuis JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, et al.:
Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis.
Ann Oncol. 2013;24:1543-8

6.) Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al.:
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?
Int J Radiat Oncol Biol Phys. 2011;81:1352-8.


Impressum                         Zuletzt geändert am 19.01.2013 9:44